English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Glioblastoma (GBM) is the most common type of brain tumor and is a worldwide health problem (1-3). The clinical symptoms of patients with GBM include include headache, nausea and vomiting. Annually, GBM has an incidence rate of approximately two to three cases per 100,000 worldwide (2-5). Despite major advances in diagnosis and treatment, the relative total 5-year survival rate remains below 10% (6-8). Recent studies have showed that complex cellular and molecular events may be implicated in prognosis of GBM. Therefore, there is an urgent need to explore the molecular and cellular alterations associated with GBM in order to develop novel therapies. Original Article

MicroRNA-221 promotes tumor progression by targeting HHIP in human glioblastoma